Page last updated: 2024-12-08

n-palmitoylglycine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-hexadecanoylglycine : An N-acylglycine in which the acyl group is specified as hexadecanoyl (palmitoyl). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID151008
CHEMBL ID226117
CHEBI ID39540
SCHEMBL ID515102
MeSH IDM0252159

Synonyms (44)

Synonym
n-palmitoyl glycine
n-ethanoyl-hexadecanamide
DB03440
2-(hexadecanoylamino)acetic acid
n-(1-oxohexadecyl)glycine
n-hexadecanoyl-glycine
LMFA08020079
n-palmitoylglycine
n-hexadecanoylglycine
NCGC00161199-02
2441-41-0
palmitoyl glycine
CHEMBL226117
ec 627-023-4
unii-m6v3riu5ki
m6v3riu5ki ,
glycine, n-(1-oxohexadecyl)-
palmitoyl glycine [inci]
timecode
palmitoilglicina
AKOS021983458
palgly
SCHEMBL515102
n-palmitoyl-gly
palmitoylglycine
2-hexadecanamidoacetic acid
HMS3604M20
DTXSID40179163
mfcd00153471
hexadecanoylglycine
CHEBI:39540
bdbm212439
n-palmitoylglycine (npg)
palgly, >=98% (hplc), solid
J-015509
n-(1-oxooctadecyl)-glycine
n-palmitoylglycine, powder
CS-0111614
Q27094364
n-palmitoyl-glycine
D76997
BS-27751
palmitoyl-glycine
HY-W074890
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
marine metaboliteAny metabolite produced during a metabolic reaction in marine macro- and microorganisms.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
fatty amideA monocarboxylic acid amide derived from a fatty acid.
N-acylglycine 16:0An N-acylglycine in which the acyl group contains 16 carbons and is fully saturated.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bifunctional cytochrome P450/NADPH--P450 reductasePriestia megaterium NBRC 15308 = ATCC 14581Kd0.14670.00400.41151.6700AID1802380
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (18)

Assay IDTitleYearJournalArticle
AID1802380Optical Titration Assay from Article 10.1074/jbc.M113.479717: \\Key mutations alter the cytochrome P450 BM3 conformational landscape and remove inherent substrate bias.\\2013The Journal of biological chemistry, Aug-30, Volume: 288, Issue:35
Key mutations alter the cytochrome P450 BM3 conformational landscape and remove inherent substrate bias.
AID287970Effect on iPGJ2 level in LPS-induced mouse RAW264.7 cells at 10 uM by ELISA2007Bioorganic & medicinal chemistry, May-15, Volume: 15, Issue:10
Potential anti-inflammatory actions of the elmiric (lipoamino) acids.
AID1140596Antiinflammatory activity in LPS-induced mouse RAW267.4 cells assessed as PGJ2 synthesis at 10 uM relative to control2014Bioorganic & medicinal chemistry, May-15, Volume: 22, Issue:10
The cannabinoid acids, analogs and endogenous counterparts.
AID387970Antiproliferative activity against rat RBL2H3 cells at 1 uM treated 1 hr before LPS-challenge assessed after 24 hrs relative to control2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
Acylamido analogs of endocannabinoids selectively inhibit cancer cell proliferation.
AID287968Effect on iPGE2 level in LPS-induced mouse RAW264.7 cells at 1 uM by ELISA2007Bioorganic & medicinal chemistry, May-15, Volume: 15, Issue:10
Potential anti-inflammatory actions of the elmiric (lipoamino) acids.
AID287964Antiproliferative activity against LPS-induced mouse RAW264.7 cells assessed as number of cells at 10 uM after 48 hrs2007Bioorganic & medicinal chemistry, May-15, Volume: 15, Issue:10
Potential anti-inflammatory actions of the elmiric (lipoamino) acids.
AID287972Effect on iPGJ2 level in LPS-induced mouse RAW264.7 cells at 1 uM by ELISA2007Bioorganic & medicinal chemistry, May-15, Volume: 15, Issue:10
Potential anti-inflammatory actions of the elmiric (lipoamino) acids.
AID287976Ratio of iPGJ2 to iPGE in LPS-induced mouse RAW264.7 cells at 1 uM by ELISA2007Bioorganic & medicinal chemistry, May-15, Volume: 15, Issue:10
Potential anti-inflammatory actions of the elmiric (lipoamino) acids.
AID387966Antiproliferative activity against human HeLa cells at 10 uM after 48 hrs relative to control2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
Acylamido analogs of endocannabinoids selectively inhibit cancer cell proliferation.
AID287962Antiproliferative activity against LPS-induced mouse RAW264.7 cells assessed as number of cells at 0.1 uM after 48 hrs2007Bioorganic & medicinal chemistry, May-15, Volume: 15, Issue:10
Potential anti-inflammatory actions of the elmiric (lipoamino) acids.
AID574406Cytotoxicity against human HaCaT cells at 50 to 100 uM after 24 hrs by MTT assay2011Bioorganic & medicinal chemistry, Feb-15, Volume: 19, Issue:4
Evaluation of endogenous fatty acid amides and their synthetic analogues as potential anti-inflammatory leads.
AID287963Antiproliferative activity against LPS-induced mouse RAW264.7 cells assessed as number of cells at 1 uM after 48 hrs2007Bioorganic & medicinal chemistry, May-15, Volume: 15, Issue:10
Potential anti-inflammatory actions of the elmiric (lipoamino) acids.
AID287974Ratio of iPGJ2 to iPGE in LPS-induced mouse RAW264.7 cells at 10 uM by ELISA2007Bioorganic & medicinal chemistry, May-15, Volume: 15, Issue:10
Potential anti-inflammatory actions of the elmiric (lipoamino) acids.
AID287966Effect on iPGE2 level in LPS-induced mouse RAW264.7 cells at 10 uM by ELISA2007Bioorganic & medicinal chemistry, May-15, Volume: 15, Issue:10
Potential anti-inflammatory actions of the elmiric (lipoamino) acids.
AID387971Antiproliferative activity against rat RBL2H3 cells at 10 uM treated 1 hr before LPS-challenge assessed after 24 hrs relative to control2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
Acylamido analogs of endocannabinoids selectively inhibit cancer cell proliferation.
AID387969Antiproliferative activity against rat RBL2H3 cells at 0.1 uM treated 1 hr before LPS-challenge assessed after 24 hrs relative to control2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
Acylamido analogs of endocannabinoids selectively inhibit cancer cell proliferation.
AID574405Antiinflammatory activity against IFN-gamma-stimulated human HaCaT cells assessed as inhibition of chemokine MDC production at 50 to 100 uM after 18 hrs by ELISA2011Bioorganic & medicinal chemistry, Feb-15, Volume: 19, Issue:4
Evaluation of endogenous fatty acid amides and their synthetic analogues as potential anti-inflammatory leads.
AID664448Inhibition of Wistar/ST rat lung NAAA assessed as conversion of [14C]PEA to [14C]palmitic acid at 100 uM after 20 mins2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
Lipophilic amines as potent inhibitors of N-acylethanolamine-hydrolyzing acid amidase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (5.56)18.2507
2000's11 (61.11)29.6817
2010's6 (33.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.51 (24.57)
Research Supply Index2.94 (2.92)
Research Growth Index5.46 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (22.22%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (77.78%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]